Ruxolitinib

Brain Glioblastoma

Baptist Health South FloridaSmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 89/ 100

Competitive context

15 Active assets in the Brain Glioblastoma cohort.

Asset / Sponsor	Phase	Rating
Disodium 4-((Tert-Butylimino)Methyl)Benzene-1,3-Disulfonate N-Oxide Oblato, Inc.	Phase 2	B
Tvi-Brain-1 TVAX Biomedical	Phase 2/3	B
Belinostat Emory University	Phase 2	CCC
Avelumab Clinique Neuro-Outaouais	Phase 2	CCC
Pembrolizumab University Hospital, Geneva	Phase 1/2	CCC

View all 22 →

Same molecule, other indications

Ruxolitinib is also rated in:

primary myelofibrosisActive

BBB

Indicative · Phase 4

73 / 100

disease related to hematopoietic stem cell transplantActive

BB

Indicative · Phase 4

70 / 100

graft versus host diseaseActive

BB

Indicative · Phase 4

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.